Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine February 2021, 62 (2) 10A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: Oliver Sartor talks with Thomas Hope, Jeremie Calais, and Wolfgang Fendler about FDA approval of 68Ga-PSMA-11 for PET imaging of prostate-specific membrane antigen–positive lesions in men with prostate cancer.

Page 146

68Ga-PSMA-11 NDA approval: Carlucci and colleagues describe the background and regulatory pathway for the academic-led New Drug Applications that facilitated FDA approval of this agent and outline implications for the larger PET community.

Page 149

Real-world data in nuclear medicine: Bourla and Herrmann look at the promise and challenges of using information generated directly from medical practice, including electronic health records, to answer research questions and address evidence gaps.

Page 156

11C dosimetry scans: Zanotti-Fregonara and colleagues suggest that performance of 11C dosimetry scans for new tracers should be abandoned in both animals and humans and replaced by a standard average dose of 5 μSv/MBq.

Page 158

FAP imaging: Altmann and colleagues review the mechanisms, recent development, and future promise of fibroblast activation protein–targeting agents in radionuclide-based approaches to diagnosis and treatment of tumors and for diagnosis of nonmalignant diseases associated with extracellular matrix remodeling.

Page 160

Quantitative nuclear cardiology: Slomka and colleagues provide the second in a series of educational overviews of the current state of quantitative clinical nuclear cardiology, here focusing on the roles of emerging and evolving analytic tools and their applications.

Page 168

Breast cancer bone assessment: van Es and colleagues compare management recommendations based on bone lesion assessment by 18F-FDG PET or 99mTc bone scintigraphy, each with contrast-enhanced CT, in patients with newly diagnosed metastatic bone cancer.

Page 177

18F-FES PET in endocrine sensitivity: Peterson and colleagues explore the use of 18F-fluoroestradiol PET imaging to elucidate the pharmacodynamics associated with histone deacetylase inhibitors and reduction of endocrine resistance in estrogen receptor–positive metastatic breast cancer.

Page 184

Immunotherapy response in mesothelioma: Ferdinandus and colleagues compare the prognostic value of volumetric PET response assessment with that of conventional criteria in patients receiving high-dose pembrolizumab for chemotherapy-resistant malignant mesothelioma.

Page 191

18F-FAC PET drug delivery imaging: Russell and colleagues correlate tumor 18F-FAC PET images with 14C-gemcitabine levels in mouse models of pancreatic cancer and determine whether changes in gemcitabine can be tracked with this imaging technique.

Page 195

FAPI-74 biodistribution: Giesel and colleagues describe evaluation of 18F-fibroblast activation protein inhibitor-74 in patients with lung cancer and document proof of mechanism for 68Ga-FAPI-74 labeled at ambient temperature.

Page 201

18F-PSMA-1007 PET/CT accuracy: Sprute and colleagues determine the diagnostic accuracy of 18F-PSMA-1007 PET/CT imaging for N-staging of prostate cancer initially and for assessment of nodal recurrence.

Page 208

68Ga-PSMA for staging in prostate cancer: Klingenberg and colleagues characterize the metastatic spread of prostate cancer in relation to tumor 68Ga-PSMA uptake and the D’Amico classification and compare primary staging results from 68Ga-PSMA PET/CT and histopathology.

Page 214

Intraarterial 90Y-DOTATOC PRRT: Lawhn-Heath and colleagues investigate whether hepatic intraarterial administration of 90Y-DOTATOC peptide receptor radionuclide therapy increases treatment efficacy while reducing systemic toxicity in neuroendocrine tumor patients with liver-dominant metastases.

Page 221

225Ac-PSMA RNT and PD-1 blockade: Czernin and colleagues combine prostate-specific membrane antigen–targeted radionuclide therapy and immunotherapy to increase tumor immunogenicity in a mouse model of prostate cancer.

Page 228

Anti–P-cadherin radioimmunotherapy: Funase and colleagues detail the preclinical pharmacokinetics and pharmacology of FF-21101, an 111In- or 90Y-conjugated monoclonal antibody against P-cadherin, to evaluate potential clinical applications.

Page 232

18F-Flortaucipir PET in neurodegeneration: Hammes and colleagues research the ability of 18F-flortaucipir PET to assess tau positivity as well as to differentiate between amyloid-positive and -negative forms of neurodegeneration on the basis of imaging signatures.

Page 240

Amyloid-β positivity and 18F-AZD4694: Therriault and colleagues analyze several methods for determining an optimal cutoff for 18F-AZD4694 PET positivity as a quantitative discriminator in neurodegeneration.

Page 247

MAO-B PET tracer 18F-SMBT-1: Harada and colleagues report on development and preclinical assessment of this promising and selective monoamine oxidase-B PET tracer candidate and discuss potential utility in quantitative monitoring of astrogliosis in the human brain.

Page 253

PET imaging of GluN2B subunits: Ahmed and colleagues investigate ortho-fluorinated and meta-fluorinated analogs of 18F-para-fluorinated-NB1, a PET probe targeting the GluN2B subunits of the N-methyl-D-aspartate receptor, with imaging potential in amyotrophic lateral sclerosis and other brain disorders.

Page 259

68Ga-FAPI PET/CT in IgG4-related disease: Luo and colleagues detail preliminary results from a prospective cohort study evaluating the performance of 68Ga-fibroblast activation protein inhibitor PET/CT in comparison with 18F-FDG PET/CT in IgG4-related disease.

Page 266

Dose–effect 166Ho radioembolization: Roekel and colleagues explore the relationship between dose and effect (i.e., response and toxicity) in colorectal cancer patients treated with 166Ho radioembolization.

Page 272

VLA-4 imaging in ALI: Haddad and colleagues evaluate targeted imaging of very late antigen-4, a key integrin mediating adhesion and recruitment of immune cells to inflamed tissues, in quantification of inflammation in a mouse model of acute lung injury.

Page 280

Ultra-fast list-mode reconstruction: Spangler-Bickell and colleagues present an infrastructure with which ultra-fast list-mode reconstructions of short PET frames (≤1 s) can be performed, producing dynamic series that can be used (among other applications) for real-time display of reconstructed data.

Page 287

  • © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (2)
Journal of Nuclear Medicine
Vol. 62, Issue 2
February 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Feb 2021, 62 (2) 10A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Feb 2021, 62 (2) 10A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Predicting Gemcitabine Delivery by 18F-FAC PET in Murine Models of Pancreatic Cancer
  • 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer
  • Preclinical Development of 18F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis
  • The Latest Developments in Imaging of Fibroblast Activation Protein
  • FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
  • Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
  • Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma
  • Real-World Data as an Evidence Source in Nuclear Medicine
  • Fibroblast Activation Protein–Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
  • Determining Amyloid-β Positivity Using 18F-AZD4694 PET Imaging
  • One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases
  • Dose–Effect Relationships of 166Ho Radioembolization in Colorectal Cancer
  • Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
  • 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer
  • 68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership
  • 18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging
  • 11C Dosimetry Scans Should Be Abandoned
  • Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors
  • Ultra-Fast List-Mode Reconstruction of Short PET Frames and Example Applications
  • Preclinical Characterization of the Radioimmunoconjugate 111In or 90Y-FF-21101 Against a P-Cadherin–Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate
  • Assessment of Bone Lesions with 18F-FDG PET Compared with 99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management
  • Quantitative clinical nuclear cardiology, part 2: Evolving/emerging applications
  • Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury
  • Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire